Brief historical overview and recent progress on cytochromes P450: Adaptation of aerobic organisms to their chemical environment and new mechanisms of prodrug bioactivation;Bref survol historique et progrès récents concernant les cytochromes P450 adaptation des organismes aérobies à leur environnement chimique et nouveaux mécanismes de bioactivation des médicaments

Annales Pharmaceutiques Francaises

Volumn 69, Issue 1, 2011, Pages 62-69

  Mansuy, D ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cytochromes P450; Drug metabolism; Oxidation; Prodrug bioactivation; Sulfenic acids; Xenobiotics

Indexed keywords

5,5 DIMETHYL 1,3 CYCLOHEXANEDIONE; ACETYLCYSTEINE; ANTICOAGULANT AGENT; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; GLUTATHIONE; PRASUGREL; PRODRUG; PURINERGIC P2Y12 RECEPTOR; THROMBOCYTE RECEPTOR; TICLOPIDINE; XENOBIOTIC AGENT;

ADAPTATION; AEROBIC BACTERIUM; ARTICLE; CHEMICAL ENVIRONMENT; DRUG ACTIVATION; DRUG MECHANISM; DRUG METABOLISM; ELECTRON SPIN RESONANCE; ENZYME SUBSTRATE COMPLEX; HUMAN; NONHUMAN; XENOBIOTIC METABOLISM;

ADAPTATION, PHYSIOLOGICAL; AEROBIOSIS; ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENVIRONMENT; FIBRINOLYTIC AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PRODRUGS;

EID: 79551594987     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2010.11.001     Document Type: Article

References (41)

1. Baillie T.A. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008, 21:129-137.
2. Testa B., Kramer S.D. The biochemistry of drug metabolism. An introduction. Part 1: principles and overview. Chem Biodiv 2006, 3:1053-1101.
3. Ortiz de Montellano P.R. Cytochrome P450: structure, mechanism and biochemistry 2005, Kluwer Academic/Plenum Publishers, New-York. Third ed.
4. Klingenberg M. Pigments of rat liver microsomes. Arch Biochem Biophys 1958, 75:376-386.
5. Garfinkel D. Studies on pig liver microsomes 1. Enzymic and pigment composition of different microsomal fractions. Arch Biochem Biophys 1958, 77:493-509.
6. Omura T., Sato R. Carbon monoxide-binding pigment of liver microsomes 1. Evidence for its hemoprotein nature. J Biol Chem 1964, 239:2370-2378.
7. Katagiri M., Ganguli B.N., Gunsalus I.C. A soluble cytochrome P450 functional in methylene hydroxylation. J Biol Chem 1968, 243:3543-3546.
8. Groves J.T., Mc Clusky G.A. Aliphatic hydroxylation via oxygen rebound-oxygen transfer catalyzed by iron. J Am Chem Soc 1976, 98:859-861.
9. Makris T.M., Denisov I., Schlichting I., Sligar S.G. Activation of molecular oxygen by cytochrome P450. Cytochrome P450: structure, mechanism and biochemistry 2005, 149-170. Kluwer Academic/Plenum Publishers, New-York. Third ed. P.R. Ortiz de Montellano (Ed.).
10. Mansuy D. Coordination chemistry of cytochrome P450 and iron porphyrins: relevance to pharmacology and toxicology. Biochimie 1978, 60:969-977.
11. Mansuy D., Battioni P., Battioni J.P. Chemical model systems for drug-metabolizing cytochrome P450-dependent monooxygenases. Eur J Biochem 1989, 184:267-285.
12. Mansuy D. A brief history of the contribution of metalloporphyrin models to cytochrome P450 chemistry and oxidation catalysis. CR Chimie 2007, 10:392-413.
13. Mansuy D., Renaud J.P. Heme-thiolate proteins different from cytochromes P450 catalyzing monooxygenations. Cytochrome P450: structure, mechanism and biochemistry 1995, 537-575. Plenum Press, New-York. Second ed. P.R. Ortiz de Montellano (Ed.).
14. Mansuy D. The great diversity of reactions catalyzed by cytochromes P450. Comp Biochem Physiol C 1998, 121:5-14.
15. Mansuy D., Battioni P. Diversity of reactions catalyzed by heme-thiolate proteins. The porphyrin handbook 2000, vol.4:1-15. Academic Press.
16. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001, 14:611-650.
17. Jousserandot A., Boucher J.L., Henry Y., Niklaus B., Clement B., Mansuy D. Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes and ketoximes. Biochemistry 1998, 37:17179-17191.
18. Poulos T.L., Finzel B.C., Gunsalus I.C., Wagner G.C., Kraut J. The 2.6-A crystal structure of pseudomonas putida cytochrome P450. J Biol Chem 1985, 260:16122-16130.
19. Williams P.A., Cosme J., Sridhar V., Johnson E.F., Mc Ree D.E. The crystallographic structure of a mammalian microsomal cytochrome P450 monooxygenase:structural adaptations for membrane binding and functional diversity. Mol Cell 2000, 5:121-132.
20. Wester M.R., Johnson E.F., Marques-Soares C., Dansette P.M., Mansuy D., Stout C.D. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 angstrom resolution: evidence for multiple substrate binding mode. Biochemistry 2003, 42:6370-6379.
21. Wester M.R., Johnson E.F., Marques-Soares C., Dijols S., Dansette P.M., Mansuy D., et al. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 angstrom resolution: evidence for an induced fit model of substrate binding. Biochemistry 2003, 42:9335-9345.
22. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450: structure, mechanism and biochemistry 2005, 377-463. Kluwer Academic/Plenum Publishers, New-York. Third ed. P.R. Ortiz de Montellano (Ed.).
23. Poulos T.L., Johnson E.F. Stucture of cytochrome P450 enzymes. Cytochrome P450: structure, mechanism and biochemistry 2005, 87-111. Kluwer Academic/Plenum Publishers, New-York. Third ed. P.R. Ortiz de Montellano (Ed.).
24. Mansuy D. Biocatalysis and substrate chemodiversity: adaptation of aerobic living organisms to their chemical environment. Catalysis Today 2008, 138:2-8.
25. Yano J.K., Hsu M.H., Griffin K.J., Stout C.D., Johnson E.F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 2005, 13:822-823.
26. Ekroos M., Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Nat Acad Sci USA 2006, 103:13682-13687.
27. Yoneda K., Iwamura R., Kishi H., Mizukami Y., Mogami K., Kobayashi S. Identification of the active metabolite of ticlopidine from rat in vitro. Br J Pharmacol 2004, 142(3):551-557.
28. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P.M., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002, 30(11):1288-1295.
29. Tuong A., Bouyssou A., Paret J., Cuong T.G. Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile. Eur J Drug Metab Pharmacokinetics 1981, 6(2):91-98.
30. Ha-Duong N.T., Dijols S., Macherey A.C., Goldstein J.A., Dansette P.M., et al. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001, 40:12112-12122.
31. Dalvie D.K., Kalgutkar A.S., Khojasteh-Bakht S.C., Obach R.S., O'Donnell J.P. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 2002, 15(3):269-299.
32. Farid N.A., Kurihara A., Wrighton S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010, 50(2):126-142.
33. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispo 2010, 38(1):92-99.
34. Dansette P.M., Libraire J., Bertho G., Mansuy D. Metabolic oxidative of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 2009, 22(2):369-373.
35. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol 2001;132(1):47-54.
36. Hasegawa M., Sugidachi A., Ogawa T., Isobe T., Jakubowski J.A., Asai F. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 2005, 94(3):593-598.
37. Williams E.T., Jones K.O., Ponsler G.D., Lowery S.M., Perkins E.J., Wrighton S.A., et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008, 36(7):1227-1232.
38. Hagihara K., Kazui M., Kurihara A., Iwabuchi H., Ishikawa M., Kobayashi H., et al. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispo 2010, 38(6):898-904.
39. Dansette P.M., Thebault S., Bertho G., Mansuy D. Formation and fate of a sulfenic acid intermediate in the metabolic activation of the antithrombotic prodrug prasugrel. Chem Res Toxicol 2010, 23:1268-1274.
40. Goto K., Shimada K., Nagahama M., Okazaki R., Kawashima T. Reaction of stable sulfenic and selenenic acids containing a bowl-type steric protection group with a phosphine. Elucidation of the mechanism of reduction of sulfenic and selenenic acids. Chem Lett 2003, 32(11):1080-1081.
41. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008, 99(3):466-472.